Loading...

Prenetics Global Limited

PRENASDAQ
Healthcare
Medical - Diagnostics & Research
$7.25
$-0.04(-0.55%)

Prenetics Global Limited (PRE) Financial Performance & Income Statement Overview

Explore the financials of Prenetics Global Limited (PRE), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
40.83%
40.83%
Operating Income Growth
7.25%
7.25%
Net Income Growth
26.18%
26.18%
Operating Cash Flow Growth
-109.77%
109.77%
Operating Margin
-119.50%
119.50%
Gross Margin
45.66%
45.66%
Net Profit Margin
-115.91%
115.91%
ROE
-27.57%
27.57%
ROIC
-29.83%
29.83%

Prenetics Global Limited (PRE) Income Statement & Financial Overview

View the income breakdown for Prenetics Global Limited PRE across both annual and quarterly reports.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$10.49M$7.78M$5.94M$6.41M
Cost of Revenue$6.59M$3.83M$2.17M$2.63M
Gross Profit$3.90M$3.95M$3.77M$3.78M
Gross Profit Ratio$0.37$0.51$0.63$0.59
R&D Expenses$2.58M$2.59M$3.03M$2.73M
SG&A Expenses$19.18M$13.12M$12.10M$10.96M
Operating Expenses$20.47M$15.76M$14.38M$13.69M
Total Costs & Expenses$27.06M$19.59M$16.55M$16.32M
Interest Income$2.04M$0.00$0.00$0.00
Interest Expense$78630.00$80552.00$27479.00$16339.00
Depreciation & Amortization$0.00$0.00$1.10M$1.72M
EBITDA-$24.89M-$12.03M-$9.51M-$8.19M
EBITDA Ratio-$2.37-$1.55-$1.60-$1.28
Operating Income-$16.57M-$11.81M-$10.61M-$9.91M
Operating Income Ratio-$1.58-$1.52-$1.79-$1.54
Other Income/Expenses (Net)-$8.40M-$304854.00-$700171.00$595897.00
Income Before Tax-$24.97M-$12.11M-$11.31M-$9.09M
Income Before Tax Ratio-$2.38-$1.56-$1.90-$1.42
Income Tax Expense-$7.42M-$75307.00-$89234.00-$285938.00
Net Income-$16.34M-$10.67M-$10.72M-$8.57M
Net Income Ratio-$1.56-$1.37-$1.80-$1.34
EPS$0.00-$0.84-$0.88-$0.70
Diluted EPS$0.00-$0.84-$0.88-$0.70
Weighted Avg Shares Outstanding$12.71M$12.71M$12.22M$12.22M
Weighted Avg Shares Outstanding (Diluted)$12.71M$12.72M$12.22M$12.22M

Over the last four quarters, Prenetics Global Limited achieved steady financial progress, growing revenue from $6.41M in Q1 2024 to $10.49M in Q4 2024. Gross profit stayed firm with margins at 37% in Q4 2024 versus 59% in Q1 2024. Operating income totaled -$16.57M in Q4 2024, maintaining a -158% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$24.89M. Net income dropped to -$16.34M, with EPS at $0.00. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;